Abstract
<h3>Background</h3> Phase 3 IKEMA study (NCT03275285) demonstrated that isatuximab (Isa) plus carfilzomib and dexamethasone (Kd) significantly improved progression-free survival (PFS) compared with Kd in patients (pts) with relapsed multiple myeloma (RMM) (hazard ratio [HR] 0.53; 99% confidence interval [CI] 0.32–0.89; P=0.0007). We evaluated efficacy and safety of Isa-Kd in East Asian pts (19 Japanese, 27 Korean) from IKEMA study. <h3>Methods</h3> RMM pts who received 1–3 prior lines of therapy were stratified to receive Isa-Kd or Kd. Isa-Kd arm received Isa (10 mg/kg intravenously) weekly for 4 weeks, then every 2 weeks. Both arms received K (20 mg/m2 Days 1–2, 56 mg/m2 thereafter) twice-weekly for 3 of 4 weeks, and d (20 mg) twice-weekly. Treatment continued until disease progression or unacceptable adverse events (AEs). The primary endpoint was PFS. Key secondary endpoints were overall response rate (ORR), very good partial response or better (≥VGPR), minimal residual disease negativity (MRD–), and complete response (CR) rates. Complete renal response (CRr, increase in eGFR from <50 mL/min/1.73 m2 at baseline to ≥60 mL/min/1.73 m2 in at least one post-baseline assessment) was also measured. <h3>Results</h3> East Asian pts (25 Isa-Kd, 21 Kd) were randomized. Pt characteristics were similar in the East Asian subgroup and the intent to treat (ITT) population (N=302). Median age (Isa-Kd 64.0 [range 45–83] years vs Kd 60.0 [33–73] years); median prior lines Isa-Kd 2.0 (1–3) vs Kd 1.0 (1–3); refractory to lenalidomide 16.0% Isa-Kd vs 47.6% Kd; refractory to proteasome inhibitor 20.0% Isa-Kd vs 33.3% Kd; high-risk cytogenetics 48.0% Isa-Kd vs 42.9% Kd. After a median follow-up of 20.7 months, PFS HR (0.64; 95% CI: 0.23–1.76) favored Isa-Kd, consistent with the HR in ITT population. ORR was high in both arms (Isa-Kd 88.0% vs Kd 81.0%); however, addition of Isa to Kd improved ≥VGPR (Isa-Kd 80.0% vs Kd 52.4%), MRD– (Isa-Kd 44.0% vs Kd 9.5%), and CR (Isa-Kd 44.0% vs Kd 23.8%) rates in East Asian pts, consistent with the ITT population (Isa-Kd vs Kd) (≥VGPR: 72.6% vs 56.9%; MRD–: 29.6% vs 13.0%; CR: 39.7% vs 27.6%). Renal response (CRr) was 100% (3/3 pts) in Isa-Kd vs 0% (0/2 pts) in Kd arm. Safety profile of Isa-Kd in East Asian pts was similar to the ITT population: Grade ≥3 AEs were observed in 79.2% Isa-Kd vs 55.0% Kd pts, serious TEAEs in 45.8% Isa-Kd vs 50.0% Kd pts, TEAEs fatal during study treatment in 0% Isa-Kd vs 5.0% Kd pts, and TEAEs leading to treatment discontinuation in 4.2% Isa-Kd vs 10.0% Kd pts. Overall, 64.0% Isa-Kd vs 42.9% Kd pts were still on treatment. <h3>Conclusions</h3> Efficacy and safety results of Isa-Kd in East Asian pts are consistent with overall IKEMA population; similar treatment effect for PFS, ≥VGPR, MRD–, and CR rates was reported in favor of Isa-Kd without an increase in the number of pts with serious TEAEs, TEAEs fatal during study treatment, or leading to discontinuations. Isa-Kd is a potential new treatment option for East Asian pts with RMM. © 2021 American Society of Clinical Oncology, Inc. Reused with permission. This abstract was accepted and previously presented at the 2021 ASCO Annual Meeting. All rights reserved.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have